Drugs / Modakafusp alfa
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05556616 | Jan 2023 → Jun 2024 | plasma cell myeloma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04392648 | Jun 2020 → Nov 2023 | refractory plasma cell neoplasm | Teva Branded Pharmaceutical Products R&D, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05590377 | Jan 2023 → May 2024 | plasma cell myeloma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04157517 | Dec 2019 → Dec 2023 | melanoma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03215030 | Oct 2017 → Jul 2024 | plasma cell myeloma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-11-05 | Takeda | Results Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting takeda.com ↗
TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-05 | Takeda | Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting takeda.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Modakafusp alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03215030 ↗ |
| Known as | TAK-573 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04392648 ↗ |
| Known as | TEV-48573 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297836 ↗ |
| Modality | Protein / enzyme biologic | “Modakafusp alfa is an immunocytokine comprising 2 attenuated interferon alfa-2b molecules and an anti-CD38 immunoglobulin G4 antibody” PMID 39630057 ↗ Feb 2025 |
| Route | Intravenous | “Modakafusp alfa intravenous infusion” NCT03215030 ↗ |
| Target | CD38 | “an anti-CD38 immunoglobulin G4 antibody, targeting delivery of interferon alfa to CD38-expressing (CD38+) immune and myeloma cells.” PMID 39630057 ↗ Feb 2025 |